Table 3 Cox regression analyses of variables for survival in non-APL AML patients
From: SLC22A3 methylation-mediated gene silencing predicts adverse prognosis in acute myeloid leukemia
Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|
HR (95% CI) | P | HR (95% CI) | P | |
Overall survival | ||||
Age (> 60/ ≤ 60 years) | 2.052 (1.322–3.184) | 0.001 | 2.590 (1.621–4.137) | < 0.001 |
WBC(≥ 30/ < 30 × 109/L) | 1.921 (1.243–2.971) | 0.003 | 1.426 (0.903–2.252) | 0.128 |
PLT(≥ 100/ < 100 × 109/L) | 1.663 (0.956–2.890) | 0.072 | 1.827 (1.037–3.219) | 0.037 |
SLC22A3 methylation (high/low) | 1.405 (0.905–2.180) | 0.129 | 2.331 (1.432–3.794) | 0.001 |
Cytogenetic classification | 1.699 (1.214–2.378) | 0.002 | 1.834 (1.291–2.606) | 0.001 |
CEBPA mutation (±) | 1.501 (0.682–3.303) | 0.312 | – | – |
NPM1 mutation (±) | 0.830 (0.379–1.820) | 0.643 | – | – |
FLT3-ITD mutation (±) | 0.822 (0.299–2.262) | 0.705 | – | – |
DNMT3A mutation (±) | 1.402 (0.507–3.872) | 0.515 | – | – |
Leukemia-free survival | ||||
Age (> 60/ ≤ 60 years) | 2.001 (0.796–5.031) | 0.140 | 7.158 (2.054–24.941) | 0.002 |
WBC (≥ 30/ < 30 × 109/L) | 2.366 (0.977–5.727) | 0.056 | 1.346 (0.508–3.570) | 0.550 |
PLT (≥ 100/ < 100 × 109/L) | 4.340 (1.391–13.539) | 0.011 | 19.235 (4.038–91.622) | < 0.001 |
SLC22A3 methylation (high/low) | 2.062 (0.841–5.056) | 0.114 | 19.856 (4.405–89.512) | < 0.001 |
Cytogenetic classification | 2.836 (1.138–7.069) | 0.025 | 11.686 (2.432–56.156) | 0.002 |
CEBPA mutation (±) | 1.587 (0.357–7.050) | 0.544 | – | – |
NPM1 mutation (±) | 0.665 (0.151–2.916) | 0.588 | – | – |
FLT3-ITD mutation (±) | 0.790 (0.104–5.991) | 0.819 | – | – |
DNMT3A mutation (±) | 1.760 (0.229–13.514) | 0.587 | – | – |